Curated News
By: NewsRamp Editorial Staff
October 01, 2025
Soligenix Secures $7.5M Funding to Advance Rare Disease Treatments
TLDR
- Soligenix secured $7.5 million in funding, extending its cash runway through 2026 to advance rare disease treatments and gain competitive advantage in biopharmaceutical markets.
- Soligenix raised $7.5 million through a public offering of 5,555,560 shares at $1.35 each, with proceeds funding R&D, commercialization, and general corporate operations.
- This funding enables Soligenix to advance treatments for rare diseases and unmet medical needs, potentially improving patient outcomes and quality of life worldwide.
- Soligenix is developing novel therapies including HyBryte for cutaneous T-cell lymphoma and heat-stabilized vaccines for diseases like Ebola and COVID-19.
Impact - Why it Matters
This financing directly impacts patients suffering from rare diseases with limited treatment options, particularly those with cutaneous T-cell lymphoma who may benefit from HyBryte's novel photodynamic therapy approach. The extended cash runway through 2026 ensures continued development of multiple therapeutic candidates across oncology, inflammatory diseases, and public health threats. For the broader healthcare landscape, Soligenix's progress represents potential breakthroughs in treating conditions that have historically received limited research attention. The company's vaccine development programs, supported by government agencies, also contribute to pandemic preparedness and biodefense capabilities, making this news relevant to both medical professionals and public health stakeholders.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing treatments for rare diseases with unmet medical needs, has successfully closed a significant $7.5 million public offering. The financing involved the sale of 5,555,560 shares of common stock and accompanying warrants at $1.35 per share, with participation from both existing and institutional healthcare investors. This strategic capital infusion is earmarked to fund the company's research and development initiatives, commercialization efforts, working capital requirements, and general corporate purposes. The transaction also included amendments to prior warrants, adjusting their exercise price to $1.35, and extends Soligenix's financial runway through the end of 2026, providing substantial operational stability for advancing their promising pipeline.
The company's Specialized BioTherapeutics segment is advancing multiple innovative treatments, including HyBryte™ (SGX301), a novel photodynamic therapy using safe visible light for cutaneous T-cell lymphoma that has completed successful Phase 3 studies and is moving toward potential global commercialization. Additional development programs include expanding synthetic hypericin (SGX302) into psoriasis treatment, dusquetide (SGX942) for inflammatory diseases including oral mucositis in head and neck cancer patients, and SGX945 for Behçet's Disease. Meanwhile, their Public Health Solutions business segment, supported by government funding from agencies including NIAID, DTRA, and BARDA, focuses on vaccine development using their proprietary ThermoVax® heat stabilization platform technology for threats including ricin toxin, filoviruses like Marburg and Ebola, and COVID-19 through their CiVax™ candidate.
This financing news is distributed through BioMedWire, which operates within the Dynamic Brand Portfolio of IBN, providing specialized communications services for the biotechnology and biomedical sectors. The platform offers comprehensive distribution solutions including wire services, editorial syndication to thousands of outlets, enhanced press release features, social media distribution to millions of followers, and tailored corporate communications strategies. For investors seeking the latest updates on Soligenix, additional information is available through the company's dedicated newsroom, accessible via the provided hyperlink, offering continuous coverage of developments from this innovative biopharmaceutical company working to address critical healthcare challenges.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix Secures $7.5M Funding to Advance Rare Disease Treatments
